Постпрандиальная гликемия: возможность надежного и эффективного контроля
Постпрандиальная гликемия: возможность надежного и эффективного контроля
Мкртумян А.М., Бирюкова Е.В., Давыдов А.Л., Маркина Н.В. Постпрандиальная гликемия: возможность надежного и эффективного контроля. Consilium Medicum. 2008; 10 (9): 19–23.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Adeghate E, Schatiner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 2006; 1084 (1): 1–29.
2. Kimmel B, Inzucchi EM. Oral Agents for Type 2 Diabetes: An Update. Clin Diab 2005; 23 (2): 64–76.
3. Shim WS, Kim SK, Kim HJ. Decremental of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006; 155 (4): 615–22.
4. Esposito K, Giugliano D, Nappo F et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110 (2): 214–9.
5. Leiter LA, Ceriello A, Davidson JA et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27(Suppl. B): S42–56.
6. Ubink-Veltman LJ, Bilo HJ, Groenier KH et al. Prevalens, incidence and mortality of type 2 diabetes mellitus revisited: a prospective populacion-based study in the Netterlands (ZODIAC-1). Eur J Epidemiol 2003; 18 (8): 793–800.
7. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61 (11): 1625–60.
8. Home PD. Postprandial hyperglycaemia: mechanisms and importance. Diabetes Obesity Metab 2000; 2 (Suppl. 1): S7–S11.
9. Ruigomez A, Rodrigues LA. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998; 14 (15): 439–45.
10. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303.
11. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22–9.
12. Guay DR. Repaglinide, a novel short-acting hypoglycaemia agent for type 2 diabetes mellitus. Pharmacotherapy 1998; 18: 1195–204.
13. Henquin JC, Garrino MG, Nenquien M. Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety glibenclamide: structural requirements and cellular mechanisms. Eur J Pharmacol 1987; 8: 11–6.
14. Owens DR. Repaglinide: prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med 15 (Suppl. 4): S28–36.
15. Johansen OE, Birkeland KI. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Am J Cardiovasc Drugs 2007; 7 (5): 319–35.
16. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? Int J Obes Relat Metab Disord 2000; 24 (Suppl. 3): S21–31.
17. Moses RG. Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets. Clin Ther 2008; 30 (3): 552–4.
2. Kimmel B, Inzucchi EM. Oral Agents for Type 2 Diabetes: An Update. Clin Diab 2005; 23 (2): 64–76.
3. Shim WS, Kim SK, Kim HJ. Decremental of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006; 155 (4): 615–22.
4. Esposito K, Giugliano D, Nappo F et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110 (2): 214–9.
5. Leiter LA, Ceriello A, Davidson JA et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27(Suppl. B): S42–56.
6. Ubink-Veltman LJ, Bilo HJ, Groenier KH et al. Prevalens, incidence and mortality of type 2 diabetes mellitus revisited: a prospective populacion-based study in the Netterlands (ZODIAC-1). Eur J Epidemiol 2003; 18 (8): 793–800.
7. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61 (11): 1625–60.
8. Home PD. Postprandial hyperglycaemia: mechanisms and importance. Diabetes Obesity Metab 2000; 2 (Suppl. 1): S7–S11.
9. Ruigomez A, Rodrigues LA. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998; 14 (15): 439–45.
10. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303.
11. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22–9.
12. Guay DR. Repaglinide, a novel short-acting hypoglycaemia agent for type 2 diabetes mellitus. Pharmacotherapy 1998; 18: 1195–204.
13. Henquin JC, Garrino MG, Nenquien M. Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety glibenclamide: structural requirements and cellular mechanisms. Eur J Pharmacol 1987; 8: 11–6.
14. Owens DR. Repaglinide: prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med 15 (Suppl. 4): S28–36.
15. Johansen OE, Birkeland KI. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Am J Cardiovasc Drugs 2007; 7 (5): 319–35.
16. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? Int J Obes Relat Metab Disord 2000; 24 (Suppl. 3): S21–31.
17. Moses RG. Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets. Clin Ther 2008; 30 (3): 552–4.
Авторы
А.М.Мкртумян, Е.В.Бирюкова,
А.Л.Давыдов, Н.В.Маркина
А.Л.Давыдов, Н.В.Маркина
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.